India’s Draft Guidelines For COVID-19 Vaccines Follow WHO, US Lead

Primary Endpoint Efficacy 50%, Secondary Up To 30%

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".